Goldman Sachs
RARE icon

Goldman Sachs’s Ultragenyx Pharmaceutical RARE Stock Holding History

Goldman Sachs’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-65,000
Closed -$1.5M – 6895
2025
Q4 		$1.5M Buy
65,000
+25,000
+63% +$822K ﹤0.01% 4832
2025
Q3 		$1.2M Buy
+40,000
New +$1.2M ﹤0.01% 4898
2021
Q2 		– Sell
-60,900
Closed -$6.93M – 6460
2021
Q1 		$6.93M Hold
60,900
– – ﹤0.01% 2864
2020
Q4 		$8.43M Buy
+60,900
New +$7.22M ﹤0.01% 2598
2020
Q3 		– Sell
-30,000
Closed -$2.35M – 5509
2020
Q2 		$2.35M Sell
30,000
-69,500
-70% -$4.6M ﹤0.01% 3342
2020
Q1 		$4.42M Buy
99,500
+69,500
+232% +$3.61M ﹤0.01% 2735
2019
Q4 		$1.28M Buy
+30,000
New +$1.24M ﹤0.01% 3961
2018
Q1 		– Sell
-26,700
Closed -$1.24M – 6304
2017
Q4 		$1.24M Sell
26,700
-12,800
-32% -$628K ﹤0.01% 4165
2017
Q3 		$2.1M Sell
39,500
-10,500
-21% -$622K ﹤0.01% 3939
2017
Q2 		$3.11M Buy
+50,000
New +$3.01M ﹤0.01% 3463
2016
Q4 		– Sell
-20,000
Closed -$1.42M – 7047
2016
Q3 		$1.42M Buy
+20,000
New +$1.28M ﹤0.01% 4098
2016
Q2 		– Sell
-35,000
Closed -$2.22M – 7204
2016
Q1 		$2.22M Buy
35,000
+100
+0.3% +$6.54K ﹤0.01% 3377
2015
Q4 		$3.92M Sell
34,900
-92,500
-73% -$9.25M ﹤0.01% 3062
2015
Q3 		$12.3M Buy
127,400
+97,400
+325% +$11.2M ﹤0.01% 2094
2015
Q2 		$3.07M Buy
30,000
+7,500
+33% +$582K ﹤0.01% 3412
2015
Q1 		$1.4M Buy
+22,500
New +$1.25M ﹤0.01% 4141
2014
Q4 		– Sell
-900
Closed -$51K – 7279
2014
Q3 		$51K Buy
+900
New +$45.3K ﹤0.01% 6809

Other funds holding RARE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Goldman Sachs's RARE Position: Q1 2026 in Review

Goldman Sachs reduced its Ultragenyx Pharmaceutical (RARE) stake by 12% in Q1 2026, selling an estimated $1.06M and leaving 353,097 shares worth $7.4M. The position accounts for ﹤0.01% of the portfolio, ranked #3325.

Goldman Sachs first reported a position in RARE in Q1 2014 and has held it in 49 quarters since. The position peaked at $121M in Q4 2020. 295 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

  • Goldman Sachs held 353,097 shares of Ultragenyx Pharmaceutical worth $7.4M as of Q1 2026.
  • Goldman Sachs sold 47,261 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $1.06M.
  • Ultragenyx Pharmaceutical made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #3325 holding.
  • Goldman Sachs first reported a position in Ultragenyx Pharmaceutical in Q1 2014 and has held it in 49 quarters since.
  • Goldman Sachs's Ultragenyx Pharmaceutical position peaked at $121M in Q4 2020.
  • 295 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.